Bafhameritin-M en es it fr

Bafhameritin-M Brand names, Bafhameritin-M Analogs

Bafhameritin-M Brand Names Mixture

  • No information avaliable

Bafhameritin-M Chemical_Formula


Bafhameritin-M RX_link

Bafhameritin-M fda sheet

Bafhameritin-M msds (material safety sheet)

Bafhameritin-M MSDS

Bafhameritin-M Synthesis Reference

No information avaliable

Bafhameritin-M Molecular Weight

241.285 g/mol

Bafhameritin-M Melting Point

230-231 oC

Bafhameritin-M H2O Solubility

20 mg/L

Bafhameritin-M State


Bafhameritin-M LogP


Bafhameritin-M Dosage Forms

Bolus; Capsule; Capsule (enteric-coated); Drops; Liquid; Lotion; Powder; Powder for solution; Shampoo; Soap bar; Solution; Stick; Syrup; Tablet; Tablet (extended-release)

Bafhameritin-M Indication

For the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.

Bafhameritin-M Pharmacology

Mefenamic acid, an anthranilic acid derivative, is a member of the fenamate group of nonsteroidal anti-inflammatory drugs (NSAIDs). It exhibits anti-inflammatory, analgesic, and antipyretic activities. Similar to other NSAIDs, mefenamic acid inhibits prostaglandin synthetase.

Bafhameritin-M Absorption

Mefenamic acid is rapidly absorbed after oral administration.

Bafhameritin-M side effects and Toxicity

Oral, rat LD50: 740 mg/kg. Symptoms of overdose may include severe stomach pain, coffee ground-like vomit, dark stool, ringing in the ears, change in amount of urine, unusually fast or slow heartbeat, muscle weakness, slow or shallow breathing, confusion, severe headache or loss of consciousness.

Bafhameritin-M Patient Information

Bafhameritin-M Organisms Affected

Humans and other mammals